Patient alliance concerning about suspension of Olital Tab development, demanding immediate actions
As patient advocates expressed concerns about suspension of the Olita Tab development, Hanmi Pharm, the Ministry of Food and Drug Safety(MFDS) and the Ministry of Health and Welfare(MOHW) insisted to prepare follow-up actions as soon as possible.
“Hanmi Pharm submitted a plan to suspend the deve...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.